olanzapine and Atherosclerosis

olanzapine has been researched along with Atherosclerosis* in 3 studies

Other Studies

3 other study(ies) available for olanzapine and Atherosclerosis

ArticleYear
Atypical antipsychotic drugs deregulate the cholesterol metabolism of macrophage-foam cells by activating NOX-ROS-PPARγ-CD36 signaling pathway.
    Metabolism: clinical and experimental, 2021, Volume: 123

    Clinical reports indicate that schizophrenia patients taking atypical antipsychotic drugs suffer from metabolism diseases including atherosclerosis. However, the mechanisms underlying the detrimental effect of atypical antipsychotic drugs on atherosclerosis remain to be explored.. In this study, we used apolipoprotein E-deficient (apoe. In vivo studies showed that genetic deletion of cd36 gene ablated the pro-atherogenic effect of olanzapine in apoe. Collectively, our results suggest that atypical antipsychotic drugs exacerbate atherosclerosis and macrophage-foam cell formation by activating the NOX-ROS-PPARγ-CD36 pathway.

    Topics: Animals; Antipsychotic Agents; Atherosclerosis; CD36 Antigens; Cholesterol; Foam Cells; Mice; Mice, Knockout; NADPH Oxidases; Olanzapine; PPAR gamma; Reactive Oxygen Species

2021
Atypical Antipsychotic Drug Olanzapine Deregulates Hepatic Lipid Metabolism and Aortic Inflammation and Aggravates Atherosclerosis.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 50, Issue:4

    Olanzapine, an atypical antipsychotic drug, has therapeutic effects for schizophrenia. However, clinical reports indicate that patients taking atypical antipsychotic drugs are at high risk of metabolic syndrome with unclear mechanisms. We investigated the effect of olanzapine on atherosclerosis and the mechanisms in apolipoprotein E-null (apoE-/-) mice.. ApoE-/- mice were used as in vivo models. Western blot analysis was used to evaluate protein expression. Conventional assay kits were applied to assess the levels of cholesterol, triglycerides, free cholesterol, cholesteryl ester, fatty acids, glycerol, and cytokines.. Daily treatment with olanzapine (3 mg/kg body weight) for four weeks increased mean arterial blood pressure and the whitening of brown adipose tissue in mice. In addition, olanzapine impaired aortic cholesterol homeostasis and exacerbated hyperlipidemia and aortic inflammation, which accelerated atherosclerosis in mice. Moreover, lipid accumulation in liver, particularly total cholesterol, free cholesterol, fatty acids, and glycerol, was increased with olanzapine treatment in apoE-/- mice by upregulating the expression of de novo lipid synthesis-related proteins and downregulating that of cholesterol clearance- or very low-density lipoprotein secretion-related proteins.. Olanzapine may exacerbate atherosclerosis by deregulating hepatic lipid metabolism and worsening hyperlipidemia and aortic inflammation.

    Topics: Adipose Tissue, White; Animals; Antipsychotic Agents; Aorta; Apolipoproteins E; Atherosclerosis; Benzodiazepines; Blood Pressure; Cholesterol; Fatty Acids; Hyperlipidemias; Inflammation; Lipid Metabolism; Liver; Male; Mice; Mice, Knockout; Olanzapine; Triglycerides

2018
[Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2015, Volume: 115, Issue:3

    To study correlations between parameters of lipid metabolism and ECG in patients with schizophrenia in light of therapy with atypical antipsychotics.. We examined 42 patients with paranoid schizophrenia. All patients received atypical neuroleptics - seroquel, zyprexa, and rispolept. A group of controls included 25 healthy people.. There was a significant increase (p=0.0002) in body mass (in average by 1.5 kg) in 88% patients. A significant increase in the concentration of serum triglycerides was identified as well. The concentration of VLDL in the patients with schizophrenia was 2 times higher compared to controls. After treatment, VLDL concentration increased even more considerably An increase in atherogenic index (AI) was up to 3.1 in patients with schizophrenia compared to 2.2 in controls. After treatment, Al increased up to 4 that demonstrated the high risk of development of atherosclerosis. A significant increase in QT interval in the ECG and heart rate (p=0.03) was revealed only in patients receiving rispolept. In patients receiving zyprexa and seroquel only heart rate was increased.. The antipsychotics studied increase the risk of development of cardiovascular pathology.. Цель исследования - изучение сопряженности показателей липидного обмена и ЭКГ у больных шизофренией в процессе терапии антипсихотическими препаратами. Материал и методы. Обследованы 42 пациента, страдающих параноидной шизофренией. Все пациенты лечились атипичными нейролептиками - рисперидоном, оланзапином и кветиапином. Группу контроля составили 25 здоровых. Результаты и заключение. Было отмечено увеличение массы тела у 88% больных в среднем на 1,5 кг (р=0,0002). Было выявлено также под влиянием терапии достоверное увеличение концентрации триглицеридов в сыворотке крови. Концентрация ЛПОНП у больных шизофренией достоверно выше, чем у здоровых в 2 раза, после терапии происходило еще более выраженное увеличение их концентрации; кроме того, у больных шизофренией имело место увеличение индекса атерогенности (ИА) до 3,1 в сравнении со здоровыми - 2,2. После терапии ИА увеличивается до 4, что свидетельствует о высоком риске развития атеросклероза. На ЭКГ отмечалось увеличение интервала QT и ЧСС (р=0,03) только у больных, принимающих рисперидон. У больных, лечившихся оланзапином и кветиапином, достоверно была увеличена только ЧСС. Сделан вывод, что лечение атипичными нейролептиками увеличивает риск развития сердечно-сосудистой патологии.

    Topics: Adult; Antipsychotic Agents; Atherosclerosis; Benzodiazepines; Dibenzothiazepines; Electrocardiography; Female; Humans; Lipid Metabolism; Lipoproteins, VLDL; Male; Middle Aged; Olanzapine; Quetiapine Fumarate; Risperidone; Schizophrenia, Paranoid; Weight Gain; Young Adult

2015